

David Tougeron

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6255311/david-tougeron-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

3,842
citations

31
h-index

57
g-index

228
ext. papers

4,931
ext. citations

3.9
avg, IF

5.05
L-index

#	Paper	IF	Citations
166	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. <i>Immunity</i> , 2016 , 44, 698-711	32.3	602
165	Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 658-667	2.2	191
164	Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. <i>Cancer Research</i> , 2015 , 75, 3446-3455	10.1	148
163	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. <i>British Journal of Cancer</i> , 2015 , 113, 989-95	8.7	121
162	Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. <i>Modern Pathology</i> , 2009 , 22, 1186-95	9.8	115
161	Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. <i>Annals of Oncology</i> , 2010 , 21, 1786-1793	10.3	111
160	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). <i>Clinical Cancer Research</i> , 2014 , 20, 3033-43	12.9	105
159	Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. <i>British Journal of Cancer</i> , 2008 , 99, 1586-92	8.7	90
158	RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. <i>Annals of Oncology</i> , 2018 , 29, 1211-1219	10.3	84
157	Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	84
156	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2013 , 24, 1267-73	10.3	79
155	Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. <i>Cancer</i> , 2015 , 121, 3290-7	6.4	77
154	TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. <i>British Journal of Cancer</i> , 2009 , 100, 1330-5	8.7	75
153	Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 51-59	13.4	73
152	Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. <i>BMC Cancer</i> , 2016 , 16, 412	4.8	73
151	Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3681-6	2.2	69
150	Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. <i>Cancers</i> , 2019 , 11,	6.6	60

149	Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. <i>Digestive Diseases and Sciences</i> , 2009 , 54, 1746-52	4	60
148	Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. <i>Cancer</i> , 2011 , 117, 1422-8	6.4	56
147	Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). <i>Annals of Oncology</i> , 2016 , 27, 121-7	10.3	55
146	Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. <i>Cancer</i> , 2013 , 119, 2765-70	6.4	54
145	Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. <i>European Journal of Cancer</i> , 2017 , 79, 158-165	7.5	53
144	Aspirin and colorectal cancer: back to the future. <i>Clinical Cancer Research</i> , 2014 , 20, 1087-94	12.9	51
143	Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells. <i>PLoS ONE</i> , 2014 , 9, e100819	3.7	49
142	Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2019 , 51, 1357-1363	3.3	41
141	Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. <i>European Journal of Cancer</i> , 2020 , 124, 91-101	7.5	40
140	Anti program death-1/anti program death-ligand 1 in digestive cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2015 , 7, 95-101	3.4	39
139	Results and challenges of immune checkpoint inhibitors in colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 561-573	5.4	38
138	ABCB4/MDR3 gene mutations and cholangiocarcinomas. <i>Journal of Hepatology</i> , 2012 , 57, 467-8	13.4	37
137	MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. <i>PLoS ONE</i> , 2013 , 8, e65369	3.7	31
136	High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	31
135	Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. <i>Digestive and Liver Disease</i> , 2012 , 44, 350-4	3.3	28
134	Association between clinicopathological characteristics and RAS mutation in colorectal cancer. <i>Modern Pathology</i> , 2018 , 31, 517-526	9.8	27
133	Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. <i>BMC Cancer</i> , 2010 , 10, 510	4.8	27
132	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , 2020 , 147, 285-296	7.5	26

131	High plasma levels of the pro-inflammatory cytokine IL-22 and the anti-inflammatory cytokines IL-10 and IL-1ra in acute pancreatitis. <i>Pancreatology</i> , 2014 , 14, 465-9	3.8	26
130	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019 , 111, 94-106	7.5	25
129	Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. <i>Oncotarget</i> , 2017 , 8, 101383-101393	3.3	25
128	Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor. <i>Neuroendocrinology</i> , 2020 , 110, 83-91	5.6	24
127	Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 1361-7	3.6	23
126	A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. <i>Clinical Cancer Research</i> , 2020 , 26, 5198-5207	12.9	23
125	Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients. <i>International Journal of Cancer</i> , 2020 , 147, 967-977	7.5	22
124	Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. <i>Neuroendocrinology</i> , 2019 , 108, 343-353	5.6	20
123	Folfirinox gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819878660	4.7	20
122	Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues. <i>Medicine (United States)</i> , 2015 , 94, e1864	1.8	20
121	Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis. <i>Oncology</i> , 2007 , 73, 328-34	3.6	20
120	Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. <i>European Journal of Cancer</i> , 2018 , 98, 1-9	7.5	20
119	Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2018 , 97, 16-24	7.5	19
118	Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 331-335	3.6	18
117	Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers. <i>PLoS ONE</i> , 2013 , 8, e61001	3.7	17
116	Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. <i>British Journal of Cancer</i> , 2018 , 118, 325-330	8.7	17
115	Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study. <i>European Journal of Cancer</i> , 2015 , 51, 925-34	7.5	16
114	Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice. <i>European Journal of Cancer</i> , 2018 , 95, 112-116	7.5	15

113	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , 2018 , 119, 424-428	8.7	15
112	Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. <i>International Journal of Cancer</i> , 2015 , 137, 1498-502	7.5	15
111	HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy. <i>Journal of Immunotherapy</i> , 2010 , 33, 402-13	5	15
110	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. <i>Digestive and Liver Disease</i> , 2016 , 48, 441-5	3.3	13
109	Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 397-403	3.5	13
108	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. <i>European Journal of Cancer</i> , 2021 , 143, 55-63	7.5	13
107	Irreversible electroporation for locally advanced pancreatic cancer. <i>Diagnostic and Interventional Imaging</i> , 2016 , 97, 1297-1304	5.4	12
106	Colonoscopy uptake for high-risk individuals with a family history of colorectal neoplasia: A multicenter, randomized trial of tailored counseling versus standard information. <i>Medicine (United States)</i> , 2016 , 95, e4303	1.8	12
105	Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?. <i>Journal of Surgical Oncology</i> , 2012 , 105, 761-6	2.8	12
104	A panel of stomach-specific biomarkers (GastroPanel [®]) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area. <i>Helicobacter</i> , 2020 , 25, e12727	4.9	12
103	Intra peritoneal abdominal fat area measured from computed tomography is an independent factor of severe acute pancreatitis. <i>Diagnostic and Interventional Imaging</i> , 2019 , 100, 421-426	5.4	11
102	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. <i>BMC Cancer</i> , 2020 , 20, 352	4.8	11
101	Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. <i>Cancers</i> , 2019 , 11,	6.6	11
100	Irreversible Electroporation for Locally Advanced Pancreatic Cancer: Where Do We Stand in 2017?. <i>Pancreas</i> , 2017 , 46, 283-287	2.6	10
99	Future perspectives of circulating tumor DNA in colorectal cancer. <i>Tumor Biology</i> , 2017 , 39, 1010428317105749	7.0	10
98	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study 2020 , 8,		10
97	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). <i>Digestive and Liver Disease</i> , 2018 , 50, 305-307	3.3	10
96	Unusual skeletal muscle metastasis from gastric adenocarcinoma. <i>Gastroenterologie Clinique Et Biologique</i> , 2009 , 33, 485-7		10

95	Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020 , 44, 295-301	2.4	10
94	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020 , 147, 3177-3188	7.5	9
93	Rebecca: a Large Cohort Study of Regorafenib (Reg) in the Real-Life Setting in Patients (Pts) Previously Treated for Metastatic Colorectal Cancer (McrC). <i>Annals of Oncology</i> , 2014 , 25, iv205	10.3	9
92	Management of esophageal adenocarcinoma. <i>Journal of Visceral Surgery</i> , 2011 , 148, e161-70	1.9	9
91	Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 39-47.e5	3.8	9
90	Characteristics of Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019 , 24, e1331-e1340	5.7	9
89	Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases. <i>Cancers</i> , 2018 , 10,	6.6	9
88	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). <i>Digestive and Liver Disease</i> , 2018 , 50, 408-410	3.3	8
87	Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. <i>ESMO Open</i> , 2021 , 6, 100120	6	8
86	Cardiovascular events in chronic hepatitis C: prognostic value of liver stiffness evolution. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 1286-92	2.2	7
85	A rare case of mantle cell lymphoma as lymphomatous polyposis with widespread involvement of the digestive tract. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011 , 35, 74-8	2.4	7
84	Where to Biopsy to Detect and How Many Biopsies Are Needed to Detect Antibiotic Resistance in a Human Stomach. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
83	Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3502-3502	2.2	7
82	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). <i>European Journal of Cancer</i> , 2021 , 150, 232-239	7.5	7
81	"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial". <i>Digestive and Liver Disease</i> , 2020 , 52, 730-733	3.3	6
80	Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfoxirinox: Results of an AGEO multicenter prospective cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4123-4123	2.2	6
79	RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11509-11509	2.2	6
78	Clinical outcome of portal vein thrombosis in patients with digestive cancers: A large AGEO multicenter study. <i>Digestive and Liver Disease</i> , 2018 , 50, 285-290	3.3	6

77	Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge. <i>Cancers</i> , 2020 , 12,	6.6	5
76	Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. <i>British Journal of Cancer</i> , 2020 , 123, 518-524	8.7	5
75	A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180). <i>Annals of Oncology</i> , 2017 , 28, v211 ^{10.3}		5
74	Absence of IDH mutation in colorectal cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2016 , 48, 681-3	3.3	5
73	A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. <i>Annals of Oncology</i> , 2017 , 28, v180	10.3	5
72	Unusual iris metastasis from anal cancer: a case report. <i>Digestive and Liver Disease</i> , 2009 , 41, e1-3	3.3	5
71	Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 518-518	2.2	5
70	Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3508-3508	2.2	5
69	Docetaxel, 5FU, oxaliplatin (TEFOX) in 1st line treatment of signet ring cell and/or poorly differentiated gastric adenocarcinoma: a retrospective study of AGEO.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15048-e15048	2.2	5
68	A large multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancers with microsatellite instability.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3536-3536	2.2	5
67	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. <i>British Journal of Cancer</i> , 2021 , 124, 1941-1948 ^{8.7}		5
66	Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. <i>Cancers</i> , 2021 , 13,	6.6	5
65	Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. <i>Targeted Oncology</i> , 2018 , 13, 107-112	5	4
64	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2016 , 48, 1498-1502 ^{3.3}		4
63	Control of pelvic symptoms in patients with rectal cancer and synchronous metastases. <i>Gastroenterologie Clinique Et Biologique</i> , 2009 , 33, 1106-13		4
62	Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 244-244	2.2	4
61	Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: A multicenter AGEO study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 94-94	2.2	4
60	Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial. <i>Colorectal Disease</i> , 2021 , 23, 1357-1369	2.1	4

59	Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). <i>Digestive and Liver Disease</i> , 2021 , 53, 306-308	3.3	4
58	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021 , 53, 420-426	3.3	4
57	Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort. <i>International Journal of Cancer</i> , 2021 , 148, 1731-1742	7.5	4
56	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021 , 53, 318-323	3.3	4
55	Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). <i>Oncology</i> , 2020 , 9, 1848058	7.2	3
54	Th-17 response and antimicrobial peptide expression are uniformly expressed in gastric mucosa of Helicobacter pylori-infected patients independently of their clinical outcomes. <i>Helicobacter</i> , 2018 , 23, e12479	4.9	3
53	Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'. <i>British Journal of Cancer</i> , 2014 , 111, 2379-80	8.7	3
52	Outcome of primary tumor in patients with synchronous stage IV colon or rectal cancer: so much the same yet so different. <i>Gastroenterologie Clinique Et Biologique</i> , 2010 , 34, e15-6		3
51	A phase IIb of erasypase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15718-e15718	2.2	3
50	Upper Gastrointestinal Lesions during Endoscopy Surveillance in Patients with Lynch Syndrome: A Multicentre Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	3
49	Prognostic factors of colorectal cancer patients with brain metastases. <i>Radiotherapy and Oncology</i> , 2021 , 158, 67-73	5.3	3
48	Endoscopy to Diagnose and Prevent Digestive Cancers in Lynch Syndrome. <i>Cancers</i> , 2021 , 13,	6.6	3
47	1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial. <i>Annals of Oncology</i> , 2020 , 31, S774	10.3	2
46	Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study). <i>Annals of Oncology</i> , 2017 , 28, v242	10.3	2
45	Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer. <i>BMC Cancer</i> , 2013 , 13, 183	4.8	2
44	Small-bowel adenocarcinoma in patient with Crohn's disease: report of a series of three cases. <i>Scandinavian Journal of Gastroenterology</i> , 2008 , 43, 1397-400	2.4	2
43	Characteristics, prognosis and treatments of 294 patients with poorly differentiated neuroendocrine carcinoma: The FFCD-GTE national cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4095-4095	2.3	2
42	Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective real life study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4036-4036	2.2	2

41	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRODIGE 71 - (FFCD 1710) phase III study. <i>Digestive and Liver Disease</i> , 2020 , 52, 1143-1147	3.3	2
40	Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). <i>Oncologist</i> , 2020 , 25, e266-e275	5.7	2
39	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 496-500	9.7	2
38	OC-0284: First results of the French cohort ANABASE : treatment and outcome in non-metastatic anal cancer. <i>Radiotherapy and Oncology</i> , 2018 , 127, S146	5.3	2
37	FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin. <i>Digestive and Liver Disease</i> , 2021 , 53, 824-829	3.3	2
36	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021 , 53, 1254-1259	3.3	2
35	Analysis of factors influencing molecular testing at diagnostic of colorectal cancer. <i>BMC Cancer</i> , 2017 , 17, 765	4.8	1
34	One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 13-13	2.2	1
33	Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4093-4093	2.2	1
32	Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4027-4027	2.2	1
31	The consensus Immunoscore adapted to biopsies in patients with locally advanced rectal cancer: Potential clinical significance for a Watch and Wait strategy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2628-2628	2.2	1
30	Prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal carcinoma (mCRC): An AGEO French multicenter retrospective cohort.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3575-3575	2.2	1
29	RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 101-101	2.2	1
28	Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas.. <i>Current Oncology</i> , 2021 , 28, 4530-4541	2.8	1
27	Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. <i>Digestive and Liver Disease</i> , 2020 , 52, 347-350	3.3	1
26	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4150-TPS4150	2.2	1
25	Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2017 , 49, 568-571	3.7	0
24	Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID).. <i>European Journal of Cancer</i> , 2022 , 166, 8-20	7.5	0

23	New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases. <i>Frontiers in Immunology</i> , 2021 , 12, 750407	8.4	o
22	Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort. <i>Future Oncology</i> , 2021 , 17, 3343-3353	3.6	o
21	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.. <i>European Journal of Cancer</i> , 2022 , 168, 34-40	7.5	o
20	Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer.. <i>Cellular and Molecular Life Sciences</i> , 2022 , 79, 284	10.3	o
19	Safety of FOLFIRI + Durvalumab + Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. <i>Biomedicines</i> , 2022 , 10, 1211	4.8	o
18	Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?. <i>JAMA Oncology</i> , 2017 , 3, 1284-1285	13.4	
17	Traitement des adéocarcinomes de l'ophage. <i>Journal De Chirurgie Viscérale</i> , 2011 , 148, 184-195	o	
16	P.327 La cinéique du CA19-9 dans le cancer du pancréas localement avancé et métastatique permet d'évaluer la réponse à la chimiothérapie. <i>Gastroenterologie Clinique Et Biologique</i> , 2009 , 33, A212		
15	Effets secondaires à long terme de la radiothérapie préopératoire des cancers rectaux. <i>Gastroenterologie Clinique Et Biologique</i> , 2006 , 30, 494-495		
14	HSP110 as a Diagnostic but Not a Prognostic Biomarker in Colorectal Cancer With Microsatellite Instability.. <i>Frontiers in Genetics</i> , 2021 , 12, 769281	4.5	
13	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS370-TPS370	2.2	
12	Three fluoropyrimidine-based regimens in second-line therapy following nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Efficacy and tolerance in clinical practice.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 370-370	2.2	
11	Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients (Pts) with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16119-e16119	2.2	
10	Withholding anti-EGFR, the impact on outcome in RAS wild-type metastatic colorectal tumors (WAIT or ACT trial).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 626-626	2.2	
9	BIONADEGE: Genomic profiling of small bowel adenocarcinoma from the NADEGE prospective cohort.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4140-4140	2.2	
8	Regorafenib (REG) in the real-life setting: First results from a large French compassionate-use program in patients (pts) with previously treated metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14599-e14599	2.2	
7	Deletions in HSP110 and prognosis in colorectal cancers with microsatellite instability.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14577-e14577	2.2	
6	The ARCAD METACER national cohort study of brain metastases in gastro-intestinal cancers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2073-2073	2.2	

- 5 High intra- and inter-tumoral heterogeneity of RAS mutations in colorectal cancer.. *Journal of Clinical Oncology*, **2016**, 34, 3577-3577 2.2
- 4 Platinum rechallenge in patients with advanced biliary tract carcinoma (ABTC) after failure of gemcitabine (GEM)-platinum combination: A national AGEO retrospective study.. *Journal of Clinical Oncology*, **2016**, 34, 4076-4076 2.2
- 3 REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.. *Journal of Clinical Oncology*, **2016**, 34, TPS4148-TPS4148 2.2
- 2 Use of the essential autophagy protein beclin 1 to regulate DNA damage response and predict response to chemoradiation in rectal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 492-492 2.2
- 1 Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational study. *Clinics and Research in Hepatology and Gastroenterology*, **2021**, 45, 101709 2.4